News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Peter A. Glassman, MBBS, MSc

Articles by Peter A. Glassman, MBBS, MSc

Pharmacy Benefits Management in the Veterans Health Administration: 1995 to 2003

ByMariscelle M. Sales, PharmD,Francesca E. Cunningham, PharmD,Peter A. Glassman, MBBS, MSc,Michael A. Valentino, RPh, MHSA,Chester B. Good, MD, MPH

February 1st 2005

Physician Satisfaction with Formulary Policies: Is it Access to Formulary or Nonformulary Drugs that Matters Most?

ByPeter A. Glassman, MBBS, MSc,Chester B. Good, MD, MPH,Mary E. Kelley, MS,Melissa Bradley, BA,Michael Valentino, RPh, MHSA

March 1st 2004

Cost-Sharing for Prescriptions of Sildenafil and Finasteride: A Case Study in Veteran Patients

ByEmily I. Yu, MPH,Peter A. Glassman, MBBS, MSc,Steven M. Asch, MD, MPH,Neil M. Paige, MD, MSHS,Leigh J. Passman, MD, PhD,Paul G. Shekelle, MD, PhD

April 1st 2001

Physician Perceptions of a National Formulary

ByPeter A. Glassman, MBBS, MSc,Chester B. Good, MD, MPH,Mary E. Kelley, MS,Melissa Bradley, BA,Michael Valentino, RPh, MHSA,John Ogden, RPh, MS

March 1st 2001

Physician and Dietitian Prescribing of a Commercially Available Oral Nutritional Supplement

ByCarrie Steigh, MPH, RD,Peter A. Glassman, MBBS, MSc,Felicitas Fajardo, MA, RD, FADA

April 1st 1998

Latest Updated Articles

Physician Satisfaction with Formulary Policies: Is it Access to Formulary or Nonformulary Drugs that Matters Most?
March 1st 2004
Physician Perceptions of a National Formulary
March 1st 2001
Pharmacy Benefits Management in the Veterans Health Administration: 1995 to 2003
February 1st 2005
Physician and Dietitian Prescribing of a Commercially Available Oral Nutritional Supplement
April 1st 1998
Cost-Sharing for Prescriptions of Sildenafil and Finasteride: A Case Study in Veteran Patients
April 1st 2001

Trending on AJMC

IRA, 340B, Medicaid: The Policy Pressures on Community Oncology

Drug Price Drives Value of MASH Therapies More Than Efficacy

Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D

Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures

Boston Experts Weigh Access, Sequencing, and Testing Across 4 Cancers